Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | OGG1 | O15527 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679606 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4ESMN1; SMN2P2RX7GRM5 | |
| SCHEMBL13188319 | 0.85 | KDM4E (0.66) | ALDH1A1KDM4ESMN1; SMN2GRM5MEN1 | |
| SCHEMBL3503418 | 0.82 | KDM4E (0.53) | ALDH1A1KDM4ESMN1; SMN2GRM5CYP1A2 | |
| SCHEMBL14809955 | 0.81 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2GRM5 | |
| SCHEMBL15228259 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1KDM4ESMN1; SMN2GRM5LOXL2 | |
| SCHEMBL3945417 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2GRM5LMNA | |
| Hydrochloric Acid SCHEMBL10707947 | 0.80 | KDM4E (0.51) | ALDH1A1KDM4ESMN1; SMN2GRM5CYP1A2 | |
| SCHEMBL231811 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2P2RX7GRM5 | |
| SCHEMBL7171815 | 0.79 | KDM4E (0.57) | ALDH1A1KDM4EP2RX7LMNAOGG1 | |
| SCHEMBL31345733 | 0.79 | P2RX7 (0.50) | ALDH1A1KDM4EP2RX7MPOCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387609-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023532-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| EP-3519397-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018060691-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018060691-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| EP-2262801-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | ALDH1A1 700/4885KDM4E 3436/4885SMN1; SMN2 482/4885 |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | ALDH1A1 700/4885KDM4E 3436/4885SMN1; SMN2 482/4885 |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | ALDH1A1 755/4885KDM4E 1237/4885SMN1; SMN2 2542/4885 |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | ALDH1A1 755/4885KDM4E 1237/4885SMN1; SMN2 2542/4885 |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | ALDH1A1 1208/4885KDM4E 2925/4885SMN1; SMN2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.